Reuters: Special Report: U.S. pharma giant profits as combination drugs flood India
“…Under India’s complex drug-approval regime, many pharmaceutical manufacturers have obtained permission from a single state to make new fixed-dose combination drugs, or FDCs, … and are selling them in other parts of the country without the approval of the central government. FDCs combine two or more drugs in a single pill. … Doctors and public health experts both in India and abroad say the proliferation and misuse of antibiotic combinations here may be contributing to antibiotic resistance, making India a potent incubator of so-called superbugs…” (Mahr et al., 12/15).